Mestinon 60

Pyridostigmine bromide, the active ingredient in Mestinon 60, is a cholinesterase inhibitor presented as a 60 mg tablet for oral use. It treats myasthenia gravis by improving neuromuscular transmission in affected patients.

GNH USA supplies Mestinon 60 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon 60, a cholinesterase inhibitor, is used primarily in disorders of neuromuscular transmission.

Myasthenia gravis: improves overall muscle strength and reduces fatigue. Ocular myasthenia: alleviates eye‑muscle weakness and double vision. Post‑operative residual neuromuscular blockade: helps reverse non‑depolarizing muscle relaxant effects.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements. - Excessive salivation: watery mouth. - Sweating: heightened perspiration. - Muscle cramps: intermittent tightening.

Serious or Rare Side Effects: - Bradycardia: unusually slow heart rate. - Cholinergic crisis: severe muscle weakness and respiratory difficulty. - Allergic reactions: rash, itching, or angioedema. - Respiratory depression: reduced breathing effort. - Seizures: rare convulsive episodes.

Mestinon 60 should be used with attention to patient‑specific factors and potential risks. - Renal impairment: adjust dose because the drug is renally excreted. - Asthma or COPD: monitor for bronchospasm due to increased secretions. - Concomitant anticholinergics: avoid antagonistic effects. - Pregnancy: safety not established; weigh benefits against risks. - Storage: Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pyridostigmine bromide may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Anticholinergic agents (e.g., atropine): block therapeutic effect. - Succinylcholine: prolonged neuromuscular blockade. - Aminoglycoside antibiotics: potentiate neuromuscular weakness.

Moderate Interactions (Monitor Closely): - Non‑depolarizing muscle relaxants: may enhance muscle weakness. - Beta‑blockers: possible additive bradycardia. - Cardiac glycosides (e.g., digoxin): monitor for arrhythmias.